Artelo Biosciences shares fall 3.51% in premarket after mixed clinical data and analyst upgrade.

Artelo Biosciences, Inc. fell 3.51% in premarket trading, following the release of preclinical data for its FABP5 inhibitor ART26.12, which showed comparable pain relief to naproxen without tolerance issues and potential safety advantages over NSAIDs, and its antidepressant candidate ART12.11, which demonstrated effects similar to sertraline in animal models, restoring cognitive function to near-baseline levels. Additionally, D. Boral Capital upgraded the company's stock rating to buy with a target price of $20.